IL1B and fatty liver disease: The MAS score and levels of pro-inflammatory markers, including IL-6, IL-1β, and TNF-α, were significantly decreased following EA administration, demonstrating the compound's efficacy in attenuating hepatic steatosis and inflammation in a dose-responsive manner (Fig. 1I–K).